Cancers, including acute lymphocytic leukaemia, acute/chronic myeloid leukaemia, pancreatic cancer, breast cancer, etc, depend on elevated RAD51 functions and enhanced HR rate for their proliferation, survival and drug resistance capabilities (Raderschall et al, 2002; Skorski, 2002; Slupianek et al, 2001; Vispe et al, 1998). Here, RAD51 is linked to cancer.